BioPharmSignal logoBioPharmSignal

Biotech News

MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MeiraGTx (MGTX)MeiraGTxCompany update

LONDON and NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced that the Compensation Committee of the Company’s Board of Directors approved equity awards under the Company’s 2026

Related news

MGTXMeiraGTx2026-07-07 11:30 EST

MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec)

TSHATaysha Gene Therapies2026-08-07 12:00 EST

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

OCULOcular Therapeutix2026-08-07 20:05 EST

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NTLAIntellia2026-08-07 20:01 EST

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ARWRArrowhead Pharmaceuticals2026-08-03 20:30 EST

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

ABEOAbeona Therapeutics2026-08-03 11:30 EST

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SRPTSarepta Therapeutics2026-07-29 21:00 EST

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

EYPTEyePoint Pharmaceuticals2026-07-16 11:00 EST

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

BCRXBioCryst Pharmaceuticals2026-07-02 11:00 EST

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

OTLKOutlook2026-05-28 20:00 EST

Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

View all latest news

MeiraGTx

MeiraGTx is a gene-therapy company focused on ophthalmology, rare disease, and genetics-based medicines. Its platform aims to deliver durable therapies to difficult-to-treat diseases.

Recent company news

MGTXMeiraGTx2026-08-06 20:30 EST

MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MGTXMeiraGTx2026-07-07 11:30 EST

MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec)

MGTXMeiraGTx2026-05-14 20:30 EST

MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MGTXMeiraGTx2026-05-14 12:00 EST

MeiraGTx Reports First Quarter 2026 Financial and Operational Results

MGTXMeiraGTx2026-04-16 11:48 EST

MeiraGTx Announces Pricing of $100 Million Offering of Ordinary Shares

Stock data

Close
12.79 USD
Market cap
855.71M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States